heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-21 and is reviewed periodically as new material appears.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
==== Absorption ==== There has been little research on psilocybin's bioavailability. Its oral bioavailability, as its active form psilocin, was about 55.0% (± ~20%) relative to intravenous administration in one small older study (n=3). After oral administration, psilocybin is detectable in the blood circulation within 20 to 40 minutes, and psilocin is detectable after 30 minutes. The mean time to peak levels for psilocin is 1.05 to 3.71 hours in different studies, with most around 2 hours and the upper limit of 3.71 hours being an outlier. Psilocybin, in terms of psilocin, shows clear linear or dose-dependent pharmacokinetics. Maximal concentrations of psilocin were 11 ng/mL, 17 ng/mL, and 21 ng/mL with oral psilocybin doses of 15, 25, and 30 mg psilocybin, respectively. The maximal levels of psilocin have been found to range from 8.2 ng/mL to 37.6 ng/mL across a dose range of 14 to 42 mg. The dose-normalized peak concentration of psilocin is about 0.8 ng/mL/mg. The interindividual variability in the pharmacokinetics of psilocybin is relatively small. There is a very strong positive correlation between dose and psilocin peak levels (R2 = 0.95). The effects of food on the pharmacokinetics of psilocybin have not been reported and are unknown, but no clear sign of food effects has been observed in preliminary analyses. It has also been said that food might delay absorption, reduce peak levels, and reduce bioavailability.
=== Glyoxylate scenario === Eschenmoser also proposed a parallel scenario where the connections between prebiotic reactions would be connected by glyoxylate, a simple α-ketoacid, produced by HCN oligomerization and hydrolysis. In this work, Eschenmoser proposes potential schemes to generate both informational oligomers and other key autocatalytic reactions from plausible one-carbon sources (HCN, CO, CO2). The Krishnamurthy group at Scripps experimentally expanded on this theory. In mild aqueous conditions, they demonstrated that the reaction of glyoxylate and pyruvate can produce a series of α-ketoacid intermediates constituting the reductive tricarboxylic acid (TCA) cycle. This reaction proceeded without metal or enzyme catalysts as glyoxylate acted as both the carbon source and reducing agent in the reaction. Similarly, the Moran group have also reported pyruvate and glyoxylate can react in warm iron-rich water to produce TCA intermediates and some amino acids. Their work has successfully reconstructed 9 out of 11 TCA intermediates and 5 universal metabolic precursors. Additional experimental analysis is needed to connect this scenario to modern metabolism.
is the initial condition. The first equation is the momentum balance equation, while the second represents the mass conservation, namely the continuity equation. Assuming constant dynamic viscosity, using the vectorial identity
In contrast, the Assad regime put more money into funding the captagon industry, transforming the country into a narcostate dependent on drug exports for revenue. Corruption ran rife after 2018, and conscripts within the SAA grew demoralized as key allies in the early years of the war such as Iran, Russia, and Hezbollah were involved in wars elsewhere.
Sources: en.wikipedia.org
== Theory == Atmosphere within the package can be modified passively or actively. In passive MAP, the high concentration of CO2 and low O2 levels in the package is achieved over time as a result of respiration of the product and gas transmission rates of the packaging film. This method is commonly used for fresh respiring fruits and vegetables. Reducing O2 and increasing CO2 slows down respiration rate, conserves stored energy, and therefore extended shelf life. On the other hand, active MA involves the use of active systems such as O2 and CO2 scavengers or emitters, moisture absorbers, ethylene scavengers, ethanol emitters and gas flushing in the packaging film or container to modify the atmosphere within the package. The mixture of gases selected for a MA package depends on the type of product, the packaging materials and the storage temperature. The atmosphere in an MA package consists mainly of adjusted amounts of N2, O2, and CO2. Reduction of O2 promotes delay in deteriorative reactions in foods such as lipid oxidation, browning reactions and growth of spoilage organisms. Low O2 levels of 3-5% are used to slow down respiration rate in fruits and vegetables. In the case of red meat, however, high levels of O2 (~80%) are used to reduce oxidation of myoglobin and maintain an attractive bright red color of the meat. Meat color enhancement is not required for pork, poultry and cooked meats; therefore, a higher concentration of CO2 is used to extend the shelf life. Levels higher than 10% of CO2 are phytotoxic for fruit and vegetables, so CO2 is maintained below this level.
==== Contemporary slavery and forced labor ==== The number of slaves today remains as high as 12 million to 27 million. This is probably the smallest proportion of slaves to the rest of the world's population in history. Most are debt slaves, largely in South Asia, who are under debt bondage incurred by lenders, sometimes even for generations. It is the fastest growing criminal industry and is predicted to eventually outgrow drug trafficking.
In Germany, rhinoplastic technique was refined by surgeons such as the Berlin University professor of surgery Karl Ferdinand von Gräfe (1787–1840), who published Rhinoplastik (Rebuilding the Nose, 1818) wherein he described 55 historical plastic surgery procedures, and his technically innovative free-graft nasal reconstruction (with a tissue-flap harvested from the patient's arm), and surgical approaches to eyelid, cleft lip, and cleft palate corrections. Dr. von Gräfe's protégé, the medical and surgical polymath Johann Friedrich Dieffenbach (1794–1847), who was among the first surgeons to anaesthetize the patient before performing the nose surgery, published Die Operative Chirurgie (Operative Surgery, 1845), which became a foundational medical and plastic surgical text (see strabismus, torticollis). Moreover, the Prussian Jacques Joseph (1865–1934) published Nasenplastik und sonstige Gesichtsplastik (Rhinoplasty and other Facial Plastic Surgeries, 1928), which described refined surgical techniques for performing nose-reduction rhinoplasty via internal incisions. In the United States, in 1887, the otolaryngologist John Orlando Roe (1848–1915) performed the first modern endonasal rhinoplasty (closed rhinoplasty) in order to treat saddle nose deformities. In America June 1894, a successful operation was reported to remove cartilage and "gratify the vanity" of a large nosed individual.
== Structural studies == As of late 2007, 29 structures have been solved for this class of enzymes, with PDB accession codes PDB: 1A27, PDB: 1BHS, PDB: 1DHT, PDB: 1EQU, PDB: 1FDS, PDB: 1FDT, PDB: 1FDU, PDB: 1FDV, PDB: 1FDW, PDB: 1GZ6, PDB: 1I5R, PDB: 1IKT, PDB: 1IOL, PDB: 1JTV, PDB: 1QYV, PDB: 1QYW, PDB: 1QYX, PDB: 1S1P, PDB: 1S1R, PDB: 1S2A, PDB: 1S2C, PDB: 1XF0, PDB: 1YB1, PDB: 1ZQ5, PDB: 2F38, PDB: 2FGB, PDB: 2HQ1, PDB: 2PD6, and PDB: 3DHE.
In this method, the proteins migrate first into a collecting gel with neutral pH, in which they are concentrated and then they migrate into a separating gel with basic pH, in which the actual separation takes place. Stacking and separating gels differ by different pore size (4-6 % T and 10-20 % T), ionic strength and pH values (pH 6.8 or pH 8.8). The electrolyte most frequently used is an SDS-containing Tris-glycine-chloride buffer system. At neutral pH, glycine predominantly forms the zwitterionic form, at high pH the glycines lose positive charges and become predominantly anionic. In the collection gel, the smaller, negatively charged chloride ions migrate in front of the proteins (as leading ions) and the slightly larger, negatively and partially positively charged glycinate ions migrate behind the proteins (as initial trailing ions), whereas in the comparatively basic separating gel both ions migrate in front of the proteins. The pH gradient between the stacking and separation gel buffers leads to a stacking effect at the border of the stacking gel to the separation gel, since the glycinate partially loses its slowing positive charges as the pH increases and then, as the former trailing ion, overtakes the proteins and becomes a leading ion, which causes the bands of the different proteins (visible after a staining) to become narrower and sharper - the stacking effect. For the separation of smaller proteins and peptides, the TRIS-Tricine buffer system of Schägger and von Jagow is used due to the higher spread of the proteins in the range of 0.5 to 50 kDa.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.